Humana

HUM

Capitalización de mercado USD 49.6 mil M

HUM's CenterWell venture with BlackRock brings $2.8 billion in capital, easing balance sheet liabilities and supporting clinic expansion.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today announced it has entered into a new joint venture agreement with funds and accounts managed by HPS Investment Partners, a part of BlackRock (“BlackRock”), to manage and operate an existing network of nearly 150 CenterWell Senior Primary Care clinics that currently sit within joint ventures owned by funds affiliated with WCAS and CenterWell. The new joint venture, majority owned by BlackRock and minority owned by CenterWell, will rep.

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) will release its financial results for the third quarter 2026 (3Q26), as well as prepared management remarks (in PDF format), at 6:00 a.m. Eastern time on November 6, 2026. The company will host a live question-and-answer session at 8:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2026. A webcast of the 3Q26 earnings call may be accessed via Humana's Investor Relations page at.

Humana (HUM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Humana's 2027 Medicare Advantage ratings rebound puts 95% of members in four-star or better plans, potentially boosting 2028 bonus payments and plan benefits.

DataMeds AI, Inc. (NASDAQ:MEDS) shares are up on Monday as traders react to Medicaid coverage policy news tied to the company's Helomics business and its ChemoFx assay.

Humana surged after its main Medicare Advantage contract regained a 4-star CMS rating for 2027, a major profit catalyst. 95% of HUM's Medicare Advantage members will be in 4-star plans, unlocking a 5% benchmark rate advantage and supporting a robust earnings outlook. I maintain a "Hold" rating as shares appear fairly valued post-rally, despite strong fundamentals, a technical breakout, and likely further sell-side upgrades.

UNH's diversified healthcare platform, improving Medicare Advantage profitability and lower valuation give it an edge over HUM.